Skip to main content

Table 1 Demographic, disease, and treatment characteristics

From: Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy

Characteristic

Lymph node positive (n = 58)

Lymph node negative (n = 78)

P-value

Median age at diagnosis (range), yrs

66.7 (50.9 – 76.8)

67.4 (48.3 – 79.1)

0.03

Mode of detection, n (%)

  

0.17

 Symptomatic

25 (43)

25 (32)

 

 Screening

33 (57)

53 (68)

Median PSA (range), ng/mL

24.4 (1.8 – 109.0)

26.0 (2.9 – 109.0)

0.26

Gleason sum, n (%)

  

0.21

 3 + 3

3 (5)

1 (1)

 3 + 4

10 (17)

8 (10)

 4 + 3

13 (22)

22 (28)

 4 + 4

23 (40)

29 (37)

 4 + 5

5 (9)

16 (21)

 5 + 4

3 (5)

2 (3)

 5 + 5

1 (2)

0 (0)

Clinical stage, n (%)

  

0.58

 T1b

1 (2)

0 (0)

 T1c

1 (2)

6 (8)

 T2a

3 (3)

1 (1)

 T2b

3 (5)

4 (5)

 T2c

3 (5)

3 (4)

 T3a

23 (40)

32 (41)

 T3b

23 (40)

30 (38)

 T4

1 (2)

2 (3)

Median duration of ADT (range), months

40.3 (11.9 – 54.4)

28.7 (9.0 – 60.2)

<0.001

  1. Abbreviations: prostate-specific antigen (PSA)